

# Whole-exome sequencing for *RH* genotyping and alloimmunization risk in children with sickle cell anemia

Stella T. Chou,<sup>1,\*</sup> Jonathan M. Flanagan,<sup>2,\*</sup> Sunitha Vege,<sup>3</sup> Naomi L. C. Luban,<sup>4</sup> R. Clark Brown,<sup>5</sup> Russell E. Ware,<sup>6</sup> and Connie M. Westhoff<sup>3</sup>

<sup>1</sup>Division of Hematology, Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, PA; <sup>2</sup>Division of Hematology, Department of Pediatrics, Baylor College of Medicine, Houston, TX; <sup>3</sup>Laboratory of Immunohematology and Genomics, New York Blood Center, New York, NY; <sup>4</sup>Department of Transfusion Medicine and Department of Pediatrics, Children's National Medical Center, Washington, DC; <sup>5</sup>Department of Pediatrics, Emory University School of Medicine, Atlanta, GA; and <sup>6</sup>Division of Hematology, Department of Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH

## Key Points

- WES can be applied for precise *RH* genotyping, detection of new or uncommon variants, and determination of *RHD* zygosity.
- An altered *RH* genotype is a risk factor for Rh alloimmunization in patients with sickle cell anemia.

*RH* genes are highly polymorphic and encode the most complex of the 35 human blood group systems. This genetic diversity contributes to Rh alloimmunization in patients with sickle cell anemia (SCA) and is not avoided by serologic Rh-matched red cell transfusions. Standard serologic testing does not distinguish variant Rh antigens. Single nucleotide polymorphism (SNP)-based DNA arrays detect many *RHD* and *RHCE* variants, but the number of alleles tested is limited. We explored a next-generation sequencing (NGS) approach using whole-exome sequencing (WES) in 27 Rh alloimmunized and 27 matched non-alloimmunized patients with SCA who received chronic red cell transfusions and were enrolled in a multicenter study. We demonstrate that WES provides a comprehensive *RH* genotype, identifies SNPs not interrogated by DNA array, and accurately determines *RHD* zygosity. Among this multicenter cohort, we demonstrate an association between an altered *RH* genotype and Rh alloimmunization: 52% of Rh immunized vs 19% of non-immunized patients expressed variant Rh without co-expression of the conventional protein. Our findings suggest that *RH* allele variation in patients with SCA is clinically relevant, and NGS technology can offer a comprehensive alternative to targeted SNP-based testing. This is particularly relevant as NGS data becomes more widely available and could provide the means for reducing Rh alloimmunization in children with SCA.

## Introduction

Transfusion management of patients with sickle cell anemia (SCA) remains a significant challenge in clinical transfusion medicine.<sup>1,2</sup> Most comprehensive sickle cell programs aim to reduce alloimmunization by providing Rh D, C, E, and K phenotype-matched red blood cells, meaning that units selected for transfusion are antigen-negative when the patient lacks the antigen.<sup>3</sup> Less often, extended phenotype matching is included for Duffy (Fya/b), Kidd (Jka/b), and MNS (Ss) blood groups.<sup>4</sup> Despite these strategies, alloimmunization to Rh antigens remains problematic even for patients transfused with phenotypic Rh antigen-matched red cells from African American donors who have similar blood group antigen profiles.<sup>5</sup> The frequency of *RH* variant alleles in this patient population contributes to the persistence of Rh alloimmunization through expression of partial or novel Rh antigen expression.<sup>5,6</sup>

The *RH* locus comprises 2 homologous genes, *RHD* and *RHCE*, which encode the D antigen and the CcEe antigens in various combinations (ce, cE, Ce, CE), respectively. The *RH* genes are highly polymorphic, particularly in individuals of African ancestry. Standard serologic Rh typing does not

**Table 1. Patient characteristics**

Characteristic	Overall SWITCH			Rh immunized			Controls			P
	Mean ± SD	No.	Female (%)	Mean ± SD	No.	Female (%)	Mean ± SD	No.	Female (%)	
No. of patients		134	46		27	67		27	56	NA
<b>Age, y</b>										
At enrollment	13.2 ± 3.9			14.9 ± 3.5			14.2 ± 3.1			.44
At first stroke	5.9 ± 2.9			7.2 ± 3.9			6.6 ± 3.0			.53
Duration of transfusions, y	7.2 ± 3.7			7.6 ± 4.6			7.6 ± 4.2			1.0

Among all 134 randomly assigned SWITCH study participants, 27 children had documented Rh immunization at study entry. Controls were identified from nonimmunized SWITCH participants and matched first for duration of transfusions (mean difference, 0.0 y; median difference, 0.0 y) and then for age at first stroke (mean difference, 0.6 y; median difference, 0.0 y). Sex was matched when possible.

NA, not applicable; SD, standard deviation.

detect the many Rh antigenic variations commonly expressed on erythrocytes from this population. These include the absence of common Rh epitopes termed “high-frequency antigens” (eg,  $hr^B$ ,  $hr^S$ ,  $HR^B$ )<sup>7</sup> and/or expression of novel Rh epitopes called “low-frequency antigens” (eg, V, VS,  $Go^a$ ) on erythrocytes.<sup>8</sup> Altered *RH* alleles encode weak and/or partial expression of D, C, e and, less often, c and E antigens. The term “partial” describes red cells that lack some common epitopes associated with expression of an antigen. As a result, patients with SCA can produce antibodies to foreign Rh epitopes they lack as well as to Rh epitopes that differ from those expressed on their own cells. It is often difficult to define the precise Rh epitope specificities of the antibodies in the plasma of immunized patients with altered *RH* alleles, because the reactivity pattern in laboratory testing can mirror that seen with an auto-antibody, yet can cause destruction of transfused cells.

We previously reported that nearly 90% of patients with SCA inherit at least 1 *RH* allele that differs from those commonly found in Europeans.<sup>5</sup> Standard serologic testing does not detect altered Rh antigen expression. Currently available DNA array and laboratory-developed assays identify the most common polymorphic *RH* alleles but cannot detect all *RH* variation. Next-generation sequencing (NGS) with either whole-genome sequencing (WGS) or whole-exome sequencing (WES) is rapidly moving toward routine practice for patients with chronic diseases and should allow comprehensive analysis of *RH* genetic variation. It was recently shown that NGS-based mapping of conventional complementary DNA-annotated erythrocyte and platelet antigens enables accurate prediction from WGS data for most blood group systems.<sup>9,10</sup> Alignment of NGS sequence reads is more difficult in the duplicated and homologous gene families, including *RHD* and *RHCE*. Application of NGS using a non-targeted WES approach for *RH* genotyping of a cohort of patients with SCA who are known to have increased *RH* genetic diversity has not previously been investigated.

The overarching goal of this study was to investigate the utility of WES for comprehensive *RH* genotyping in children with SCA. We analyzed WES data from 54 children with SCA (27 Rh alloimmunized and 27 non-alloimmunized) randomly assigned in the SWITCH (Stroke With Transfusions Changing to Hydroxyurea; NCT 00122980) study.<sup>11</sup> Specific goals were to compare the accuracy of a WES approach to current single nucleotide polymorphism (SNP)-based testing and to determine associations of Rh antibody production with the *RH* genotype.


## Methods

### Study population, phenotyping, and DNA extraction

SWITCH had an average age at enrollment of 13 years with approximately 7 years of transfusion duration.<sup>11</sup> A total of 161 patients were enrolled from 2006 to 2010, all with at least 18 months of chronic transfusions to prevent secondary stroke. Most participating institutions provided prophylactic C-, E-, K-matched transfusions. All patients had their transfusion history and antibody records reviewed, and data were recorded at study entry. We identified 27 patients in the randomized cohort ( $n = 134$ ) with known Rh antibodies at enrollment. We paired a matched control for each alloimmunized patient with an unrelated patient of similar age who had a similar number of years of transfusion exposure and the same sex when possible but with no alloimmunization (Table 1). Patients with *RH* and *RHAG* genotypes were compared with patients from Children’s Hospital of Philadelphia who received prophylactic C-, E-, K-matched transfusions from minority donors. Patient enrollment, clinical data collection, and sample analysis were conducted with approval by the institutional review boards at Baylor College of Medicine and CHP. Genomic DNA was extracted from whole blood by using standard methods and was stored at  $-20^{\circ}\text{C}$  until analysis.

### *RH* genotyping

DNA samples were tested with *RHD* and *RHCE* BeadChip DNA arrays (Bioarray, Warren, NJ) and polymerase chain reaction (PCR)-based assays, as described previously.<sup>5,12</sup> Briefly, the DNA array targets 35 *RHD* and 25 *RHCE* single nucleotide changes or insertions. PCR- restriction fragment length polymorphism-based analysis was performed for *RHD* exon 8 (c.1136C>T) and *RHCE* exon 2 (c.254C>G), exon 4 (c.577A>G), and exon 6 (c.907 del C). *RHD* exons 2 and 7 were amplified, and Sanger sequencing was performed to distinguish some alleles. Discordant results between SNP-based assays and WES were investigated with Sanger sequencing of implicated exons that were amplified by using *RHCE*- and/or *RHD*-specific primers as previously described.<sup>13</sup> *RHD* zygosity was determined by direct amplification of a 1507-bp fragment from the region associated with deletion of *RHD*,<sup>14</sup> and for some, *RHD* zygosity was also determined by *Pst*I-restriction fragment length polymorphism.<sup>15</sup> *RHD* and *RHCE* alleles were assigned on the basis of either a single or a combination of genetic markers and haplotype associations based on reported alleles.<sup>5,16,17</sup>



**Figure 1. Anti-Rh and anti-K in SWITCH patients at trial enrollment.** (A) The number and specificity of antibodies identified in 27 patients who are either negative or positive for the corresponding antigen by serologic testing. (B) The number of patients with partial Rh antigens (and no corresponding conventional allele) determined by high-resolution *RH* genotyping and at risk of alloantibody ( $n = 27$  Rh alloimmunized and 27 non-alloimmunized at enrollment).

## WES

WES data were generated by using NimbleGen VCRome 2.1 capture reagents, followed by sequencing on an Illumina HiSeq platform. Individual sequence reads were aligned to the reference human genome, and variants were annotated. All samples passed WES quality control parameters with an average of 92% of all exonic regions sequenced at greater than 20 $\times$  coverage per sample. A project-level variant call format was generated for each sample and included all *RHD* and *RHCE* gene variations present in at least 1 sample.

Sequencing reads were mapped to the GRCh37/hg19 reference genome by using the Burrows-Wheeler algorithm.<sup>18</sup> Sample-level genome variants were identified and annotated by using an integrated *Mercury* pipeline<sup>19</sup> which includes quality score recalibration, genome variant identification by AtlasSNP,<sup>20</sup> and annotation using Cassandra software. All reagents and data processing are standard methods used for WES and were not adjusted to focus analysis on *RHD* and *RHCE*.

## RHAG (V270I) genotyping

We used Applied Biosystems StepOne (Applied Biosystems, Foster City, CA) PCR systems to perform a TaqMan assay for the *RHAG* SNP c.808G>A (rs16879498) associated with p.Val270Ile. After 40 amplification cycles, threshold cycle values were automatically calculated, and the individual SNP genotypes were determined by StepOne v2.0 software (Applied Biosystems). Samples from 54 individuals from the SWITCH cohort and 488 individuals with SCA from CHP were tested.

## Statistical analysis

We performed genetic case-control comparison by using Fisher's exact test or Pearson's  $\chi^2$  test. Phenotypes (groups) were classified as Rh alloimmunized or non-alloimmunized. An additive genetic model was used for testing, with adjustment for age, sex, and population stratification when possible. Any variant with an association having a  $P$  value below .05 was considered significant, although none of the  $P$  values remained statistically significant when adjusted for the number of multiple comparisons. For the WES data analysis of candidate genes, quality control filtering steps included minimum sequence coverage of 10 $\times$ , SNP missingness check, and application of an excess heterozygosity filter.

## Results

### Rh immunization in SWITCH study participants

Among 134 randomly assigned SWITCH study participants, 27 patients (20.1%) had a history of antibodies to Rh antigens at

study entry. Controls were identified from non-alloimmunized SWITCH participants (Table 1) and matched first for duration of transfusions (mean difference, 0.0 years; median difference, 0.0 years) and then for age at first stroke (mean difference, 0.6 years; median difference, 0.0 years). The mean duration of transfusions was 7.6 years for both groups, and the mean age at first stroke was 7.2 years for the Rh immunized and 6.6 years for the control group ( $P = .53$ ; Table 1). There were more females in the Rh alloimmunized group compared with the overall SWITCH cohort ( $P < .04$ ). From antibody data reported at study entry, there were 4 anti-D, 10 anti-C, 3 anti-C<sup>w</sup>, 1 anti-c, 18 anti-E, and 3 anti-e antibodies among the 27 Rh-immunized patients (Figure 1A; supplemental Table 1). Fourteen (35.8%) of these 39 Rh antibodies were unexpected in that they were present in individuals who typed positive by serology for that antigen. The remaining 25 Rh antibodies (8 anti-C, 1 anti-C<sup>w</sup>, and 16 anti-E) were found in patients who were antigen-negative by serologic testing. The finding of anti-K is consistent with lack of antigen matching and was identified in 4 Rh-alloimmunized individuals (Figure 1A).

### RH genotyping by SNP assay

Samples were tested by a combination of DNA array and PCR-based assays targeting markers of *RHD* (supplemental Table 2) and *RHCE* (supplemental Table 3) gene variation. Overall, 9 different *RHD* and 13 *RHCE* alleles were identified by either single or combinations of markers among this cohort, of which 5 *RHD* and 8 *RHCE* are reported to encode partial Rh antigens defined as lacking antigenic epitopes (Table 2). Two alleles that differ from the conventional alleles, *RHD*\*DAU0 and *RHCE*\*ce48C, encode single amino acid changes and are common in African populations. These alleles have not been reported to encode proteins lacking epitopes or to encode novel epitopes (ie, partial antigens). Exceptions may exist, but patients with these alleles seem to be at less risk for Rh alloimmunization than patients with other altered alleles (our unpublished observations).

Overall, *RH* allele frequencies were similar between Rh alloimmunized and non-immunized individuals ( $P > .05$ ; data not shown). *RH* allele frequencies also did not differ significantly from 488 patients from the CHP cohort, some of whom have been previously reported, with the exception that *RHCE*\*ceS was more frequent in the CHP cohort ( $P = .0408$ ).<sup>5</sup> Analysis of the comprehensive *RH* genotypes for each individual revealed that 14 Rh alloimmunized patients were predicted to express known altered or partial Rh antigens without co-expression of conventional protein compared with 5 non-immunized individuals (51.9% vs 18.5%;  $P = .0103$ ) (supplemental Table 1). Variant e and/or c (ie, *RHCE*\*ce) were the

**Table 2. Comparison of allele frequencies between participants in the SWITCH trial (n = 54) and children with SCA from CHP (n = 488)**

Rh genotype	Rh phenotype	Diagnostic nucleotide changes (cDNA)	SWITCH cohort	CHP cohort	P
<b>RHD*</b>					
Deleted D	D-		0.1666	0.1445	.5678
Inactive D <sub>1</sub>	D-	In3-19 (37 bp), 609G>A, 654G>C, 667T>G, 674C>T, 807T>G	0.0185	0.0297	.7616
<i>DIIIa-CE(4-7)-D</i>	D-, partial C+	186G>T, 410C>T, 455A>C	0.0648	0.0277	.0721
<i>D</i>	D+		0.5648	0.5410	.7601
<i>DAU0</i>	D+ (unknown)	1138C>T	0.1019	0.1619	.1239
<i>DAU3</i>	Partial D+	835G>A, 1138C>T	0.0278	0.0113	.1588
<i>DAR</i>	Partial D+	602C>G, 667T>G, 1025C>T	0.0093	0.0041	.4116
<i>D 4.0</i>	Partial D+	602C>G, 667T>G	0.0278	0.0256	.7553
<i>DIIIa</i>	Partial D+	186G>T, 410C>T, 455A>C, 602C>G, 667T>G	0.0185	0.0123	.6435
Others			NA	0.0419	NA
<b>RHCE*</b>					
<i>ce</i>	c+, e+		0.2407	0.2490	.9068
<i>Ce</i>	C+, e+	48G>C, 150T>C, 178C>A, 201A>G, 203A>G, 307C>T	0.0926	0.1199	.4360
<i>cE</i>	c+, E+	676G>C	0.0463	0.0871	.1969
<i>ce48C</i>	c+, e+ (unknown)	48G>C	0.2130	0.1926	.6118
<i>ce48C 733G</i>	Partial c+, partial e+	48G>C, 733C>G	0.0556	0.0686	.6911
<i>ce733G</i>	Partial c+, partial e+	733C>G	0.1852	0.1455	.3200
<i>ce254G</i>	Partial c+, partial e+	254C>G	0.0370	0.0471	.8107
<i>ce1025T</i>	Partial c+, partial e+	1025C>T	0.0093	0	.1005
<i>ceJAL</i>	Partial c+, partial e+	340C>T, 733C>G	0.0093	0.0010	.1909
<i>ceCF</i>	Partial c+, partial e+	48G>C, 697C>G, 733C>G	0.0093	0.0020	.2724
<i>ceS</i>	Partial c+, partial e+	48G>C, 733C>G, 1006G>T	0.0833	0.0379	.0408
<i>ceAR</i>	Partial c+, partial e+	48G>C, 712A>G, 733C>G, 787A>G, 800T>A, 916A>G	0.0093	0.0031	.3457
<i>cE48C</i>	c+, E+ (unknown)	676G>C, 48G>C	0.0093	0.0010	.1909

The allele frequency was similar (two-sided Fisher's exact test). Only the specific alleles shared by both groups are shown. The alleles in the SWITCH cohort comprised 95.8% of *RHD* and 95.5% of *RHCE* alleles also present in the larger CHP cohort.  
cDNA, complementary DNA.


most common variants in both the Rh alloimmunized and the non-immunized children (Figure 1B). Correlation of unexpected Rh antibodies (present in individuals who typed positive for the antigen; n = 14) revealed 1 anti-D, 1 anti-C, and 1 anti-e in 3 patients with altered alleles and absence of the conventional allele (supplemental Table 1). Anti-C<sup>w</sup> in 2 C+ patients can likely be explained by exposure to altered C antigen (C<sup>w</sup>) present in 2% of white donors. Nine Rh specificities (3 anti-D, 1 anti-C, 1 anti-c, 2 anti-E, 2 anti-e) in 8 patients remain unexplained (antibody present in patient with conventional allele). However, with 1 exception (unique patient identifier [UPID] 75 whose anti-e would be classified as an autoantibody; supplemental Table 1), 7 of these individuals have altered *RH* genotypes.

### RH genotype by WES

We then examined whether analysis of WES data covering *RHD* and *RHCE* gene loci agreed with results from *RH* genotyping by SNP-based methods. The publicly available NGS analysis pipeline *Mercury*<sup>19</sup> was used to integrate multiple sequence analysis components across many computational steps and to provide a fully

annotated list of variants (Figure 2). We assessed concordance for detection of SNPs between the 2 methods and performed Sanger re-sequencing for discordant samples. Good-coverage exome data were generated for 9 of 10 *RHD* exons (median coverage, 19×-317×) and all *RHCE* exons (39×-297×; supplemental Tables 2 and 3). *RHD* exon 8 had low sequence coverage (median coverage, <6×; Figure 3A), and therefore WES did not reliably detect the c.1138C>T change (p.Thr379Met) in exon 8 that has an allele frequency of 0.1019 to 0.1710 in African individuals (Table 2).<sup>5,16</sup> WES also did not detect the *RHD* 37-bp duplication that inactivates D antigen expression (D- phenotype) referred to as the *RHD* pseudogene (supplemental Table 2). However, the *RHD* pseudogene has the stop codon c.807T>G (p.Try269Stop) in exon 6 that was identified by WES. Finally, as expected for exon-only interrogation, WES cannot detect the *RHCE* 109-bp intron 2 insertion in *RHCE*\**Ce* associated with a C+ phenotype (supplemental Table 3).

Determining the C+ phenotype by using WES data requires an alternative approach. Exon 2 of *RHD* and *RHCE*\**Ce* share identical sequences, and *RHCE*\**Ce* exon 2 WES sequence reads will map




**Figure 2. Mercury analysis pipeline.** (A) Raw data from the sequencing instrument is passed to primary analysis software to generate sequence reads and base call confidence values (qualities). (B) Reads and qualities are passed along to a mapping tool Burrows-Wheeler algorithm (BWA) for comparison with a reference genome. The placement of reads on the reference genome produces a Binary-format Sequence Alignment Map (BAM) file and individual event BAMs were merged to make a single sample-level BAM file. (C) AtlasSNP and Genome Analysis Toolkit (GATK) are used to identify variants and produce annotated variant call files (VCFs). (D) In this study, we specifically interrogated WES data for the *RHD* and *RHCE* genes compared with conventional targeted assays.

to *RHD* exon 2. To overcome this, we calculated read depth ratios of each sample for *RHCE* exons 1, 2, and 3 and compared the average value for all samples. Patients with *RHCE*\**Ce* have a reduced ratio for exon 2 (fewer reads) compared with exons 1 and

3 (Figure 3B). By using this approach, all 10 C+ individuals with *RHCE*\**Ce* were identified. One individual (UPID 19) was identified as having an *RHCE*\**Ce* allele with WES, whereas SNP array demonstrated *RHCE*\**cE/cE*.

**Figure 3. WES coverage for *RHD* and *RHCE* genes.** (A) The median number of individual sequence reads are given for each polymorphism identified by exome sequencing. The sequence reads were aligned to the human reference sequence GRCh37, and median coverage was calculated for the entire SWITCH cohort (n = 134). All exons (rectangles) had greater than 10× median coverage except *RHD* exon 8 (marked in red). (B) Normalized sequence read depth for *RHCE* exons 1, 2, and 3 (n = 54). Individuals with *RHCE*\**Ce* have a reduced ratio for exon 2 compared with exons 1 and 3 (orange bar). (C) Normalized sequence read depth for *RHD*, *RHCE*, and neighboring genes (n = 54). Genes with 2 copies are indicated as black bars, 1 copy as orange bars, and no copies as red bars.





**Table 3. Summary of discordance between WES and SNP methods designated by nucleotide position in cDNA and RH exon that were resolved by Sanger re-sequencing**

Reason	cDNA position	Exon	WES	SNP array	Sanger re-sequencing	Sample UPIDs
<i>RHCE</i> nucleotide assigned to <i>RHD</i> by WES	RHD c.186G>T	2	G/T	G/G	G/G	10
	RHD c.602C>G	4	C/G	G/G	G/G	60
	RHD c.667T>G	5	T/G	G/G	G/G	60
	RHD c.697G>C	5	G/C	G/G	G/G	84
<i>RHD</i> nucleotide assigned to <i>RHCE</i> by WES	RHCE c.410C>T	3	C/T	C/C	C/C	7, 50, 82
	RHCE c.654G>C	5	G/C	G/G	G/G	39
	RHCE c.916A>G	6	A/G	A/A	A/A	67, 104
Misassignment as a result of reference sequence	RHCE c.48G>C	1	G/C	G/G	G/G	33, 81, 124
	RHCE c.48G>C	1	C/C	G/C	G/C	38, 85
WES detects changes not included in SNP testing	RHD c.916G>A	6	G/A	NT	G/A	28, 81
	RHCE c.941T>C	7	T/C	NT	T/C	89, 102

NT, not tested.

### WES and SNP concordance

Comparison of WES and DNA array SNP genotypes demonstrated differences in 19 samples involving 10 nucleotide positions (Table 3). Sanger re-sequencing was performed for each discordant result. Alignment of sequence reads to the homologous *RH* gene was the primary reason for discordant WES assignments. Four hemizygous and/or homozygous G nucleotide positions in *RHD* were identified as heterozygous by WES: c.186G>T in exon 2, c.602C>G in exon 4, and c.667T>G and c.697G>C in exon 5. For a heterozygous call, a sequence ratio of 50:50 is expected. For each of these calls, 11% to 13% of sequence reads were *RHCE* sequences that were assigned to *RHD*. The integrated *Mercury* pipeline used to process the WES data interpreted any polymorphism with reference-to-variant sequence reads greater than 90% of total as being homozygous. A slight relaxation of this threshold to 85% of total calls would have resulted in all of these *RHD* markers called as homozygous.

The converse, alignment of *RHD* sequence reads to *RHCE* by WES, occurred in 6 samples (Table 3). The c.410C>T change in exon 3 from the *RHD* locus hybrid *RHD\*DIIIa-CE(4-7)-D* was assigned to *RHCE* in 3 samples, as was the c.654G>C change in exon 5 from the *RHD* pseudogene in 1 sample and the c.916A>G in exon 6 in 2 samples. As with *RHD*, relaxation of the *Mercury* pipeline reference:variant ratio threshold would have resulted in concordant calls for *RHCE* c.410C/C, c.654G/G, and c.916A/A. Five samples were discordant for *RHCE* c.48G>C. Exon 1 of the *RH* genes has only this 1 coding polymorphic nucleotide position between *RHD* and some but not all *RHCE* alleles, but the human genome reference sequence for *RHCE* lists c.48C as wild-type, which also complicates allelic assignment by NGS. Relaxation of the reference:variant ratio threshold would have resulted in 1 of these calls being concordant with DNA array SNP testing.

Four samples had changes identified by WES that were not identified by SNP assays. WES detected an *RHD* exon 6 change c.916G>A in 2 samples (UPID 28 and 81) associated with *RHD\*weak D type 66*, and the exon 7 *RHCE* change c.941T>C in 2 samples (UPID 89 and 102). These polymorphisms have been previously reported but are not interrogated by SNP assay. Overall, the concordance between the genotyping methods ranged from

91.7% to 100% for *RHD* and *RHCE* polymorphisms (supplemental Tables 2 and 3).

### Determination of *RHD* zygosity

*RHD* zygosity can be determined by analysis of *RHD* exon copy number compared with *RHCE* exon copy number. With very rare exceptions, 2 *RHCE* alleles are present in all samples, and in most populations, the D- phenotype results from deletion of *RHD*.<sup>15</sup> To determine *RHD* copy number, we generated an average read depth ratio between the entire *RHD* and *RHCE* genes (Figure 3C). For patients with homozygous deletion (absence) of *RHD* (n = 2), the sequence read depth was zero for *RHD* but reached an average of 104 ± 56 reads for *RHCE* (1.0 normalized read depth ratio) representing 2 copies of *RHCE*. By using a calculated read depth ratio, 23 patients had 1 copy (0.62 ± 0.09 read depth ratio), and 29 patients had 2 copies of *RHD* (1.20 ± 0.11 read depth ratio) (supplemental Table 4). We compared these results to *RHD* zygosity determined by PCR methods. Fifty-three (98%) of 54 were concordant. One sample by WES analysis was *RHD* hemizygous but gave conflicting results (D-/- and D+/-) by 2 different PCR-based methods.

### Search for genetic associations with Rh alloimmunization

RhD and RhCE proteins physically associate with Rh-associated glycoprotein (RhAG), CD47, LW, and glycophorin B in a larger Rh complex in the erythrocyte membrane. We hypothesized that mutations in these proteins may alter Rh epitopes or topology and contribute to recognition of the Rh complex as foreign, with subsequent antibody production. WES data were therefore also examined for polymorphisms in *RHAG*, *CD47*, *LW*, and *GYPB*. Among the SWITCH cohort, no variant in *CD47*, *LW*, *GYPB*, or *RHAG* was significantly different between the Rh alloimmunized group compared with the non-immunized group. Eight (14.8%) of 54 SWITCH participants were heterozygous for the V270I variant, of which 5 were Rh-immunized and 3 were non-immunized (18.5% vs 11.1%; *P* = .70). RhAG is important for targeting RhD and RhCE to the erythrocyte membrane, and gene-inactivating mutations in *RHAG* are responsible for loss of Rh antigen expression (Rh-null).<sup>21</sup> The *RHAG* V270I (c.808G>A change) variant was previously

reported to encode the RHAG4 antigen in a familial case with maternal sensitization and hemolytic disease in her newborn.<sup>22</sup> To ensure that an association of RHAG V270I was not detected because of the small sample size of the SWITCH cohort, we further investigated possible significance in a larger cohort of 488 individuals with SCA from CHP. The overall frequency of the RHAG V270I variant was similar: 14.6% (n = 71) were heterozygous and 0.6% were homozygous (n = 3). Among patients with at least 10 unit exposures (n = 157; median exposure, 178 units; mean, 341 units), there was no difference in the frequency of the RHAG V270I variant in the Rh alloimmunized (9 of 60) compared with non-alloimmunized (15 of 97) individuals (15.0% vs 15.5%;  $P = 1.0$ ).

## Discussion

RH genetic diversity contributes to the prevalence of Rh antibodies encountered after red cell transfusion in patients with SCA.<sup>5,6,23</sup> Importantly, Rh antibodies continue to occur in patients who receive donor units that are antigen-matched by serology for Rh D, C, and E antigens because of RH variation at the genetic level. We previously reported that individuals who express only altered or partial Rh antigen (and no corresponding conventional protein) are at increased risk of alloimmunization.<sup>5</sup>

We RH genotyped a matched cohort of SWITCH trial participants to extend our studies on RH variation and to assess whether Rh antibody formation correlated with specific RH alleles in a multicenter cohort. Genotyping revealed that RH diversity in the SWITCH participants parallels that seen in our previously reported CHP cohort.<sup>5</sup> At enrollment, 20.1% of SWITCH participants were Rh alloimmunized and, consistent with our previous observations, 36% of these Rh antibodies were unexpected in that patients were positive for the corresponding antigen. Comparison of 27 Rh alloimmunized with 27 non-alloimmunized individuals matched for age and transfusion years indicated that Rh alloimmunization was correlated to inheritance of altered RH alleles ( $P = .0103$ ). Although only 3 of the antibodies (1 anti-D, 1 anti-C, 1 anti-e) could be directly explained by inheritance of the corresponding partial antigen and absence of conventional protein, 11 additional Rh-immunized patients expressed at least 1 partial Rh antigen, further supporting our previous suggestion that the presence of any partial Rh may disrupt the Rh complex and contribute to Rh alloimmunization.<sup>5</sup>

The Rh antibodies found in this population challenge convention in that patients whose erythrocytes are positive for an antigen, or patients who were never exposed to the antigen, are not expected to have the corresponding antibody identified by the laboratory as present in their plasma. Thus, RH genotyping has a potentially important role in transfusion support for patients with SCA to resolve confusing serologic antibody reactivity and to guide selection of units for transfusion. Currently available DNA arrays identify the most common polymorphic RH alleles but cannot detect all RH variation, require expertise to interpret, may be cost prohibitive for some, and are not widely available. Alternatives would advance patient care, especially if they involve translation of data that may already be available. WGS and WES are moving toward routine practice for patients with many chronic diseases and should allow comprehensive analysis of RH genetic variation in patients with SCA. Examining whether WES data can be accurately aligned and interpreted, given the challenges of duplicated genes with significant homology, provides proof of concept for the development of targeted NGS panels for RHD and RHCE.

**Table 4. Summary of RH alleles that require modification of data analysis or algorithm for assignment**

Genotype	RBC phenotype	cDNA location	Genomic coordinates	Consideration for correct assignment
RHD*DAU0	D+	Exon 8, c.1138C>T (p.Trp379Met)	NC_000001.11:g.25317062T>C	Reference sequence and increased genomic coverage
RHCE*ce48C	c+e+	Exon 1, c.48G>C (p.Trp16Cys)	NC_000001.11:g.25420739G	Reference sequence and increased genomic coverage
RHD*Ce	C+	109-bp intron 2 insertion	NC_000001.11:g.25732088-25732107	Exon copy number calculation
RHD*Dpsi	D-	37-bp insertion	NC_000001.11:g.25627431-25627454dup	Use of stop codon to detect
RHD*DI/la-CE(4-7)-D	C+ partial, D-	Exons 4-7	NA	Detection of novel insert for assignment to RHD rather than RHCE

NT, not tested; RBC, red blood cell.

In this study, WES data using a standard non-targeted approach with modified analysis pipelines to identify *RH* variants and determine *RHD* zygosity demonstrated a high concordance rate with SNP typing. Comprehensive *RH* genotypes for 49 (90.7%) of 54 SWITCH participants in this study were concordant with SNP-based assays. The 4 discordant *RHCE* exon 1 c.48C alignment challenges would not have an impact on risk for clinically significant antibody production or donor choice, because *RHCE\*ce48C* has not been associated with partial antigen expression. Alignments for *RHCE* vs *RHD* in exon 1, which differ only by 1 nucleotide (c.48) in some but not all *RHCE* alleles, require greater read depth with algorithm adjustment. The other limitation was the very low sequence coverage for *RHD* exon 8 (median coverage, <6×), which was supported by examination of the ExaC database, which shows poor coverage of *RHD* exon 8 in more than 60 000 individuals with WES data. A recent study that designed targeted exome sequencing for blood group systems encountered similar limitations in coverage and sequence alignment for exons 1 and 8 of *RHD* and *RHCE*.<sup>24</sup>

Approaches used here to improve accuracy included a slight relaxation of the *Mercury* pipeline reference:variant ratio threshold, consideration of *RHCE* exon 2 copy number to detect the C<sup>+</sup> phenotype associated with *RHCE\*Ce*, and recognition of the common hybrid allele *RHD\*DIIIa-CE(4-7)-D* as an *RHD* locus variant (Table 4). In the future, standardization of the human genome reference sequence and increased coverage of exon 1 for *RHCE\*ce48C* and exon 8 for *RHD\*1138T* detection would further enhance accuracy (Table 4).

Analysis of NGS data for 36 blood group systems from the 1000 Genomes Project demonstrated extensive variation in a multiethnic cohort.<sup>25</sup> Of the 1241 nonsynonymous variants identified in the coding regions, only 241 were known blood group polymorphisms. Therefore, performing NGS-based *RH* predictions on a diverse population of serologically and molecularly typed individuals will be necessary to further refine interpretation algorithms. The development of sequencing technology that allows longer read lengths, targeted NGS panels for the *RH* loci, and automated algorithms for interpretation will further improve accuracy, availability, and affordability.

Interrogation of our WES data to identify polymorphisms in other membrane proteins known to interact physically with RhD and RhCE was unrevealing. Although the *RHAG* V270I variant was identified in 15% of the SWITCH and CHP cohorts, it was not

associated with expression of RhAG4 antigen (not shown) and was not associated with a higher risk for Rh immunization. Similar to prior studies looking for genetic polymorphisms associated with alloimmunization risk, our relatively small sample size (n = 54 and n = 488) is a limitation.

Recognition of *RH* variants can refine antibody identification, improve red blood cell matching, and potentially minimize alloimmunization in patients with SCA. We demonstrate that WES data can be used for accurate prediction of Rh antigen expression in patients with SCA who have tremendous *RH* genetic variation, and adjustments will increase accuracy. In the future, improved *RH* genotyping technology and accessibility may allow consideration of both recipient and donor *RH* genotypes and ultimately reduce Rh alloimmunization in individuals with SCA.

## Acknowledgments

The authors thank the patients and families who enrolled in the studies, members of the Immunohematology and Genomics Laboratory at the New York Blood Center, the Human Genome Sequencing Centre at Baylor College of Medicine for assistance in generating the whole-exome sequencing data, and Perry Evans for statistical support.

This work was supported by the Doris Duke Innovations in Clinical Research Award grants 2013151 (S.T.C., C.M.W., and R.E.W.), 2011097, and 2015133 (S.T.C. and C.M.W.); by National Institutes of Health (NIH) National Human Genome Research Institute award U54-HG003273 (R.E.W.); by NIH National Heart, Lung, and Blood Institute award HL-078787 for the SWITCH study (R.E.W.); and in part by a donation from the DiGaetano family (S.T.C.).

## Authorship

Contribution: S.T.C., J.M.F., R.E.W., and C.M.W. designed the study, analyzed results, and wrote the manuscript; S.V. conducted research and analyzed results; N.L.C.L. was the SWITCH transfusion consultant; R.C.B. enrolled patients and collected data for the SWITCH study; and N.L.C.L. and R.C.B. edited the manuscript.

Conflict-of-interest disclosure: The authors declare no competing financial interests.

Correspondence: Stella T. Chou, The Children's Hospital of Philadelphia, 3615 Civic Center Blvd, Abramson Research Center, Room 316D, Philadelphia, PA 19104; e-mail: chous@email.chop.edu.

## References

1. Chou ST, Liem RI, Thompson AA. Challenges of alloimmunization in patients with haemoglobinopathies. *Br J Haematol*. 2012;159(4):394-404.
2. Yazdanbakhsh K, Ware RE, Noizat-Pirenne F. Red blood cell alloimmunization in sickle cell disease: pathophysiology, risk factors, and transfusion management. *Blood*. 2012;120(3):528-537.
3. Afenyi-Annan A, Willis MS, Konrad TR, Lottenberg R. Blood bank management of sickle cell patients at comprehensive sickle cell centers. *Transfusion*. 2007;47(11):2089-2097.
4. Lasalle-Williams M, Nuss R, Le T, et al. Extended red blood cell antigen matching for transfusions in sickle cell disease: a review of a 14-year experience from a single center (CME). *Transfusion*. 2011;51(8):1732-1739.
5. Chou ST, Jackson T, Vege S, Smith-Whitley K, Friedman DF, Westhoff CM. High prevalence of red blood cell alloimmunization in sickle cell disease despite transfusion from Rh-matched minority donors. *Blood*. 2013;122(6):1062-1071.
6. Sippert E, Fujita CR, Machado D, et al. Variant RH alleles and Rh immunisation in patients with sickle cell disease. *Blood Transfus*. 2015;13(1):72-77.



7. Noizat-Pirenne F, Lee K, Pennec PY, et al. Rare RHCE phenotypes in black individuals of Afro-Caribbean origin: identification and transfusion safety. *Blood*. 2002;100(12):4223-4231.
8. Daniels GL, Faas BH, Green CA, et al. The VS and V blood group polymorphisms in Africans: a serologic and molecular analysis. *Transfusion*. 1998;38(10):951-958.
9. Lane WJ, Westhoff CM, Uy JM, et al; MedSeq Project. Comprehensive red blood cell and platelet antigen prediction from whole genome sequencing: proof of principle. *Transfusion*. 2016;56(3):743-754.
10. Giollo M, Minervini G, Scalzotto M, Leonardi E, Ferrari C, Tosatto SC. BOOGIE: predicting blood groups from high throughput sequencing data. *PLoS One*. 2015;10(4):e0124579.
11. Ware RE, Helms RW; SWiTCHe Investigators. Stroke With Transfusions Changing to Hydroxyurea (SWiTCHe). *Blood*. 2012;119(17):3925-3932.
12. Westhoff CM, Vege S, Hipsky CH, et al. RHCE\*ceAG (254C>G, Ala85Gly) is prevalent in blacks, encodes a partial ce-phenotype, and is associated with discordant RHD zygosity. *Transfusion*. 2015;55(11):2624-2632.
13. Westhoff CM, Vege S, Wylie D, et al. The JAL antigen (RH48) is the result of a change in RHCE that encodes Arg114Trp. *Transfusion*. 2009;49(4):725-732.
14. Chiu RW, Murphy MF, Fidler C, Zee BC, Wainscoat JS, Lo YM. Determination of Rhd zygosity: comparison of a double amplification refractory mutation system approach and a multiplex real-time quantitative PCR approach. *Clin Chem*. 2001;47(4):667-672.
15. Wagner FF, Flegel WA. RHD gene deletion occurred in the Rhesus box. *Blood*. 2000;95(12):3662-3668.
16. Reid ME, Hipsky CH, Hue-Roye K, Hoppe C. Genomic analyses of RH alleles to improve transfusion therapy in patients with sickle cell disease. *Blood Cells Mol Dis*. 2014;52(4):195-202.
17. International Society of Blood Transfusion. Red Cell Immunogenetics and Blood Group Terminology. 2016. Available at: <http://www.isbtweb.org/working-parties/red-cell-immunogenetics-and-blood-group-terminology/>. Accessed 10 April 2017.
18. Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. *Bioinformatics*. 2009;25(14):1754-1760.
19. Reid JG, Carroll A, Veeraraghavan N, et al. Launching genomics into the cloud: deployment of Mercury, a next generation sequence analysis pipeline. *BMC Bioinformatics*. 2014;15:30.
20. Challis D, Yu J, Evani US, et al. An integrative variant analysis suite for whole exome next-generation sequencing data. *BMC Bioinformatics*. 2012;13:8.
21. Cherif-Zahar B, Raynal V, Gane P, et al. Candidate gene acting as a suppressor of the RH locus in most cases of Rh-deficiency. *Nat Genet*. 1996;12(2):168-173.
22. Reid ME, Lomas-Francis C, Olsson ML. The Blood Group Antigen FactsBook. 3rd ed. San Diego, CA: Elsevier Academic Press; 2012.
23. Tournamille C, Meunier-Costes N, Costes B, et al. Partial C antigen in sickle cell disease patients: clinical relevance and prevention of alloimmunization. *Transfusion*. 2010;50(1):13-19.
24. Schoeman EM, Lopez GH, McGowan EC, et al. Evaluation of targeted exome sequencing for 28 protein-based blood group systems, including the homologous gene systems, for blood group genotyping. *Transfusion*. 2017;57(4):1078-1088.
25. Möller M, Jöud M, Story JR, Olsson ML. ErythroGene: a database for in-depth analysis of the extensive variation in 36 blood group systems in the 1000 Genomes Project. *Blood Advances*. 2016;1:240-249.